• 1. Essential effect of the electrolyte on the mechanical and chemical degradation of LiNi0.8Co0.15Al0.05O2 cathodes upon long-term cycling??
  Xiaoming Liu,Zachary D. Hood,Wangda Li,Donovan N. Leonard,Arumugam Manthiram,Miaofang Chi J. Mater. Chem. A, 2021,9, 2111-2119
• 2. Establishing the accuracy of position-specific carbon isotope analysis of propane by GC-pyrolysis-GC-IRMS
  ChangjieLiu,PengLiu,XiaofengWang,XiaoqiangLi,JuskeHorita
• 3. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 4. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 5. Fe(iii)-mediated isomerization of α,α-diarylallylic alcohols to ketones via radical 1,2-aryl migration?
  Ziyang Deng,Changwei Chen,Sunliang Cui RSC Adv., 2016,6, 93753-93755

Recent Advances in Isoquinolin-1-ylmethanamine Hydrochloride (CAS: 1177303-46-6) Research: A Comprehensive Review

Isoquinolin-1-ylmethanamine hydrochloride (CAS: 1177303-46-6) is a chemical compound of significant interest in the field of medicinal chemistry and drug discovery. This compound, characterized by its isoquinoline scaffold, has garnered attention due to its potential pharmacological applications, particularly in the development of novel therapeutic agents. Recent studies have explored its synthesis, biological activity, and potential as a lead compound in various disease models. This research brief aims to provide an up-to-date overview of the latest findings related to Isoquinolin-1-ylmethanamine hydrochloride, highlighting its chemical properties, mechanisms of action, and therapeutic potential.

The synthesis of Isoquinolin-1-ylmethanamine hydrochloride has been optimized in recent years to improve yield and purity, making it more accessible for research and development. Advanced synthetic routes, including multi-step organic reactions and catalytic processes, have been reported in peer-reviewed journals. These methods not only enhance the efficiency of production but also allow for the introduction of structural modifications that can fine-tune the compound's biological activity. Researchers have particularly focused on the role of the hydrochloride salt form in improving solubility and bioavailability, which are critical factors for drug development.

In terms of biological activity, Isoquinolin-1-ylmethanamine hydrochloride has demonstrated promising results in preclinical studies. Its mechanism of action appears to involve interactions with various molecular targets, including enzymes and receptors implicated in inflammatory and neurodegenerative diseases. For instance, recent in vitro studies have shown that this compound exhibits inhibitory effects on key enzymes involved in oxidative stress pathways, suggesting potential applications in conditions such as Alzheimer's disease and Parkinson's disease. Additionally, its modulatory effects on neurotransmitter systems have sparked interest in its use as a potential anxiolytic or antidepressant agent.

One of the most significant advancements in the research of Isoquinolin-1-ylmethanamine hydrochloride is its evaluation in cancer models. Preliminary data indicate that this compound may interfere with cell proliferation and induce apoptosis in certain cancer cell lines. These findings are particularly relevant given the ongoing search for novel chemotherapeutic agents with improved selectivity and reduced side effects. Researchers are currently investigating the compound's structure-activity relationship to identify derivatives with enhanced potency and specificity against various cancer types.

Despite these promising developments, challenges remain in the clinical translation of Isoquinolin-1-ylmethanamine hydrochloride. Pharmacokinetic studies are needed to fully understand its absorption, distribution, metabolism, and excretion profiles. Furthermore, comprehensive toxicological assessments must be conducted to ensure its safety profile meets regulatory standards for human use. Collaborative efforts between academic institutions and pharmaceutical companies are crucial to advancing this compound through the drug development pipeline.

In conclusion, Isoquinolin-1-ylmethanamine hydrochloride (CAS: 1177303-46-6) represents a versatile chemical entity with substantial potential in medicinal chemistry. Recent research has shed light on its synthetic accessibility, diverse biological activities, and therapeutic applications across multiple disease areas. As investigations continue to unravel its full pharmacological potential, this compound may emerge as a valuable tool for drug discovery and a promising candidate for further development. The coming years are likely to witness significant progress in understanding and harnessing the therapeutic benefits of this intriguing molecule.

• 132833-03-5(Isoquinolin-3-ylmethanamine)
• 40615-08-5(Isoquinolin-1-ylmethanamine)
• 1628557-04-9(Isoquinolin-3-ylmethanamine hydrochloride)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)